GT Biopharma, Inc. short interest in 2023
In 2023, GT Biopharma, Inc.'s disclosed short interest ran from 0.79% of shares outstanding on 13 Jan 2023 to 0.16% on 15 Dec 2023, a change of -0.63 percentage points. The year's high was 0.79% on 13 Jan 2023 and its low 0.16% on 15 Dec 2023, averaging 0.51% across 20 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 4.73 days on 31 Mar 2023. Full history: GT Biopharma, Inc..
Cite this page
By year: 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2023 in figures
- Start of year
- 0.79% (13 Jan 2023)
- End of year
- 0.16% (15 Dec 2023)
- Change
- -0.63 pp
- High
- 0.79% (13 Jan 2023)
- Low
- 0.16% (15 Dec 2023)
- Average
- 0.51%
- Highest days to cover
- 4.73 (31 Mar 2023)
- SEC filings marked
- 4
Every report in 2023
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 13 Jan 2023 | 0.79% | 4.62 | |
| 31 Jan 2023 | 0.74% | 3.15 | |
| 15 Feb 2023 | 0.59% | 1.14 | |
| 28 Feb 2023 | 0.56% | 1.40 | |
| 15 Mar 2023 | 0.77% | 2.93 | |
| 31 Mar 2023 | 0.60% | 4.73 | 10-K filed |
| 14 Apr 2023 | 0.60% | 1.27 | |
| 28 Apr 2023 | 0.44% | 1.00 | |
| 15 May 2023 | 0.38% | 1.00 | 10-Q filed |
| 31 May 2023 | 0.36% | 1.00 | |
| 15 Jun 2023 | 0.56% | 1.00 | |
| 30 Jun 2023 | 0.61% | 1.00 | |
| 14 Jul 2023 | 0.60% | 1.00 | |
| 31 Jul 2023 | 0.50% | 1.00 | |
| 15 Aug 2023 | 0.56% | 1.36 | 10-Q filed |
| 29 Sep 2023 | 0.25% | 1.00 | |
| 13 Oct 2023 | 0.39% | 1.90 | |
| 31 Oct 2023 | 0.33% | 1.73 | |
| 15 Nov 2023 | 0.37% | 1.05 | 10-Q filed |
| 15 Dec 2023 | 0.16% | 1.00 |
See also: GT Biopharma, Inc.'s full history · most shorted US stocks of 2023 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.